ArticleJournal of translational medicine2013
TIMP3 and CCNA1 hypermethylation in HNSCC is associated with an increased incidence of second primary tumors.
Article in Journal of translational medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Pooled it
- Diagnostic accuracy of DNA methylation for head and neck cancer varies by sample type and number of markers tested.Oncotarget · 2016Pooled it
- Correlation of CCNA1 promoter methylation with malignant tumors: a meta-analysis introduction.BioMed research international · 2015Pooled it
- Decoding the mechanisms behind second primary cancers.Journal of translational medicine · 2025Review
- Two by Two Factorial Design using Metformin and Curcumin for Second Primary Head and Neck Cancer Prevention Trial.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Promoter DNA methylation patterns in oral, laryngeal and oropharyngeal anatomical regions are associated with tumor differentiation, nodal involvement and survival.Oncology letters · 2024Article
- Genomic alterations in oral multiple primary cancers.International journal of oral science · 2024Article
- Salivary DNA Methylation as an Epigenetic Biomarker for Head and Neck Cancer. Part II: A Cancer Risk Meta-Analysis.Journal of personalized medicine · 2021Review
- Head and Neck Squamous Cell Carcinoma: Epigenetic Landscape.Diagnostics (Basel, Switzerland) · 2020Review
- Hypermethylation status of DAPK, MGMT and RUNX3 in HPV negative oral and oropharyngeal squamous cell carcinoma.Genetics and molecular biology · 2020Article
- Association between SFRP promoter hypermethylation and different types of cancer: A systematic review and meta-analysis.Oncology letters · 2019Article
- Promoter Hypermethylation of Tumor-Suppressor GenesBiomolecules · 2019Article
- Susceptibility of Multiple Primary Cancers in Patients With Head and Neck Cancer: Nature or Nurture?Frontiers in oncology · 2019Review
- Aberrant DNA methylation of theJournal of Cancer · 2018Article
- Genomic profile of oral squamous cell carcinomas with an adjacent leukoplakia or with an erythroleukoplakia that evolved after the treatment of primary tumor: A report of two cases.Molecular medicine reports · 2017Article
- Article
- Plasma levels of the tissue inhibitor matrix metalloproteinase-3 as a potential biomarker in oral cancer progression.International journal of medical sciences · 2017Article
- Salivary DNA methylation panel to diagnose HPV-positive and HPV-negative head and neck cancers.BMC cancer · 2016Article
- Prognostic value of aberrant promoter hypermethylation of tumor-related genes in early-stage head and neck cancer.Oncotarget · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypermethylation in the promoter regions is associated with the suppression of gene expression and has been considered a potential molecular marker for several tumor types, including head and neck squamous cell carcinomas (HNSCC).
methodsTo evaluate the gene hypermethylation profile as a prognostic marker, this retrospective study used a QMSP approach to determine the methylation status of 19 genes in 70 HNSCC patients.
resultsThe methylation profile analysis of primary HNSCC revealed that genes CCNA1, DAPK, MGMT, TIMP3 and SFRP1 were frequently hypermethylated, with high specificity and sensitivity. TIMP3 and CCNA1 hypermethylation was significantly associated with lower rates of second primary tumor-free survival (p = 0.007 and p = 0.001; log-rank test, respectively).
conclusionThis study, for the first time, presents CCNA1 and TIMP3 hypermethylation as a helpful tool to identify HNSCC subjects at risk of developing second primary carcinomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.